1 Maternally transferred monoclonal antibodies protect neonatal mice from herpes
2 simplex virus-induced mortality and morbidity.

3 Iara M. Backes^{1,2}, Brook K. Byrd², Chaya D. Patel¹, Sean A. Taylor¹, Callaghan R.
4 Garland¹, Scott W. MacDonald³, Alejandro B. Balazs³, Scott C. Davis², Margaret E.
5 Ackerman^{1,2*} & David A. Leib^{1*}

6 ¹Department of Microbiology and Immunology, Geisel School of Medicine at Dartmouth,
7 Lebanon, NH 03756, USA.

8 ²Thayer School of Engineering, Dartmouth College, Hanover, NH 03755, USA.

9 ³Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.

10 *Corresponding authors

11 Margaret E. Ackerman
12 14 Engineering Dr,
13 Hanover, NH 03755
14 margaret.e.ackerman@dartmouth.edu
15 (ph) 603 646 9922
16 (fax) 603 646 3856

17 David A. Leib
18 One Medical Center Drive HB 7556
19 Lebanon, NH 03756
20 david.a.leib@dartmouth.edu
21 (ph) 603-650-8616
22 (fax) 603-650-6223
23

24 *Conflict of Interest Statement*

25 A patent has been filed by Dartmouth with I.M.B., C.D.P., D.A.L., and M.E.A. as
26 inventors partially based on these results.

Abstract

Neonatal herpes simplex virus (HSV) infections often result in significant mortality and neurological morbidity despite antiviral drug therapy. Maternally-transferred HSV-specific antibodies reduce the risk of clinically-overt neonatal HSV (nHSV), but this observation has not been translationally applied. Using a neonatal mouse model, we tested the hypothesis that passive transfer of HSV-specific human monoclonal antibodies (mAbs) can prevent mortality and morbidity associated with nHSV. The mAbs were expressed *in vivo* by vectored immunoprophylaxis, or administered *in vivo* following recombinant expression *in vitro*. Through these maternally-derived routes or through direct administration to pups, diverse mAbs to HSV glycoprotein D protected against neonatal HSV-1 and HSV-2 infection. Using *in vivo* bioluminescent imaging, both pre- and post-exposure mAb treatment significantly reduced viral load. Administration of mAb also reduced nHSV-induced behavioral morbidity, as measured by anxiety-like behavior. Together these studies support the notion that HSV-specific mAb-based therapies may prevent or improve HSV infection outcomes in neonates.

Introduction

Among perinatal viral infections, neonatal herpes simplex virus (nHSV) infection has the highest infant mortality rate (1, 2). Transmission most often occurs during birth or via close contact with an infected individual in the first few days of life (3). It is estimated that there are 14,000 cases of nHSV per year globally (4) and recent studies suggest rising incidence in the United States (5). nHSV presents clinically in three forms: skin, eye, and mouth (SEM), central nervous system (CNS), and disseminated disease in the visceral organs. Despite aggressive antiviral treatment with acyclovir, mortality subsequent to disseminated disease remains high (30%), and CNS disease is associated with ~70% neurological morbidity and 25% mortality (6, 3, 7). This disease burden highlights the urgent need to augment clinical interventions in nHSV infections. Promisingly, maternal infection and serostatus is highly predictive of nHSV acquisition. The greatest risk (30-50%) is to vaginally delivered neonates born to seronegative mothers with primary or first-time genital infection (3, 7–9). In contrast, only ~3% of infections result from reactivated genital HSV disease, suggesting that maternal seroconversion and subsequent placental and/or milk transfer of antibodies protect the neonate from HSV infection (7–10). While many factors inform the relative risk of infant infection (10), there is a strong association between high titers of functionally potent anti-HSV maternal antibodies (Abs) and the absence of disseminated infection in neonates (11). Supporting these clinical observations, maternal seropositivity induced by vaccination, infection, or passive transfer of polyclonal HSV-specific IgG during pregnancy, reduced the risk of mortality and/or neurological morbidity in mouse pups (12–14).

However, only certain HSV-specific mAbs targeting envelope glycoproteins prevent ocular (15), genital (16, 17), and systemic HSV disease in adult mouse models (18, 19). Given the high susceptibility of neonatal mice to HSV infection, it is of interest to investigate whether mAbs that show efficacy in adult mice also prevent disease in neonatal mice. In agreement with adult mouse studies, protection in newborn mice depends on epitope specificity, with protection afforded by select mAbs or polyclonal antigen-specific Ab preparations (20). Here we evaluated a set of four human IgG₁ mAbs that target the viral entry mediator glycoprotein D (gD), which is found on the HSV-1 and HSV-2 envelope as well as the surface of infected cells (15, 21–23), for their efficacy in preventing HSV mortality and morbidity in a neonatal mouse infection model.

Given the evidence that polyclonal maternal antibodies are naturally protective against nHSV, we hypothesized that maternally transferred mAbs could have therapeutic utility. To address this, dams were given an injection of recombinant mAbs, or adeno-associated virus (AAV) vectored antibody delivery (24), a strategy that can protect adult animals from viral (25–27) and parasitic infections (28), but which has not been evaluated for its ability to provide transgenerational protection in the form of maternally transferred Abs. Together our work demonstrates that maternal or direct administration of mAbs can ameliorate or prevent this devastating neonatal disease, motivating clinical investigation.

Results

mAb UB-621 accumulates at the placental-fetal interface. While maternal Abs prevent nHSV mortality and morbidity (12, 29), their biodistribution in pregnant dams has not

been fully elucidated. To preserve the complex anatomy of the placental-fetal interface we pursued hyperspectral imaging via whole body cryo-macrotome processing (30), which causes minimal disruption to these tissues (Figure 1). We administered fluorescently labeled UB-621 mAb to pregnant C57BL6 (B6) dams two days before sacrifice and tissue preparation. Two dams (naive and UB-621 infused) were immediately processed for cryo-imaging after sacrifice, while an additional dam was further dissected to prepare conceptuses for cryo-imaging. Robust fluorescent signal of tissues at the placental-fetal interface was detected in the cryo-imaged dam infused with fluorescent UB-621 as compared to the control dam that did not receive mAb (Figure 1A and 1B, Supplemental Video 1). To confirm that this signal originated from tissues at the maternal-fetal interface, conceptuses were individually harvested from the maternal uterus and individually imaged with different layers of placental-fetal and/or fetal tissues dissected (Figure 1C). These dissection experiments confirmed that mAb accumulated at the placental-fetal interface, and was also detected in fetal and maternal tissues (Supplemental Figure 1). Notably, high fluorescence was observed in a harvested conceptus where the visceral yolk sac, a tissue rich in expression of the neonatal Fc receptor (FcRn) necessary for IgG transfer (31), remained intact (Figure 1C, middle image). Overall, this technique allowed us to visualize IgG traversing the circulation of the pregnant dam and entering maternal and fetal membranes.

HSV mAbs targeting glycoprotein D protect neonatal mice from HSV-1 and HSV-2 mortality. The mAbs used in this study span the gD ectodomain, with epitopes close to the herpes virus entry mediator (HVEM) binding domain, and the Nectin (1 & 2) binding

domains (Figure 2A). The gD:mAb interfaces between E317/UB-621, CH42 and CH43 have been resolved in detail through crystallography and alanine scanning (15, 21), while that of HSV8 is more broadly defined from binding experiments with truncated gD (32) (Figure 2B). Each of these mAbs protect from HSV infection in adult mouse models (Supplemental Table 1), and two (E317/UB-621 and HSV8) are currently in clinical trials (E317/UB-621: NCT02346760, NCT03595995, NCT04714060, NCT04979975, HSV8: NCT02579083). Like human neonates, mouse pups are highly susceptible to HSV infection, succumbing to infection at low viral doses relative to adult mice (33, 34). Therefore, we wished to determine if HSV gD-specific mAbs could protect mouse pups from HSV-1 infection. Pregnant dams were administered either CH42 or control IgG approximately 3-5 days before parturition, and pups were challenged intranasally with HSV-1 one day after birth (Figure 3A). Offspring of dams treated with CH42 showed significantly improved survival ($p < 0.001$) compared to offspring of control IgG-treated dams.

While prophylactic approaches for nHSV are desirable, we also sought to model therapeutic approaches to treat extant infections in neonates that may more closely model the clinical setting. To understand the prophylactic and therapeutic effect of mAb treatment, we administered E317 or control mAb one day *before* viral challenge, and given results with prophylactic maternal CH42 treatment, we administered CH42 or control mAb one day *after* viral challenge. Pups treated with E317 or CH42 exhibited improved survival ($p=0.06$ and $p < 0.05$, respectively) relative to pups that received control IgG (Figure 3B).

We next assessed the protection afforded by mAbs currently being evaluated in clinical trials for adult genital HSV disease (HSV8 and UB-621) (22, 35) (E317/UB-621: NCT02346760, NCT03595995, NCT04714060, NCT04979975, HSV8: NCT02579083). HSV8, UB-621, CH42, or control IgG were administered to pups, then mice were immediately challenged with HSV-1. Both HSV8 and UB-621 mAbs completely protected pups from mortality following HSV-1 viral challenge ($p < 0.001$). In contrast, CH42 afforded partial protection compared to control IgG-treated pups ($p < 0.01$) (Figure 3C, left panel).

While HSV-1 genital disease predominates in the Americas and Western Pacific, and continues to rise as the etiologic agent of genital disease in high income countries, HSV-2 remains a significant cause of neonatal disease. Therefore, pups were treated with HSV8, UB-621 and CH42 as described above and challenged with HSV-2 (Figure 3C, right panel). Each HSV-specific mAb tested resulted in significantly improved (UB-621 $p < 0.001$, CH42 and HSV8 $p < 0.01$) survival of pups challenged with HSV-2 as compared to control IgG-treated pups. Collectively, these data showed that gD-specific mAbs can protect highly susceptible neonatal mice when administered via disparate routes, at different doses of antibody, and before and after viral challenge with either HSV-1 or HSV-2.

mAb CH42 reduces CNS and disseminated viral replication. Disseminated disease results in the highest case fatality rate among nHSV clinical presentations, and despite aggressive antiviral treatment, has an unacceptably high mortality (30%) (7). We therefore assessed the impact of mAb therapy in the control of viral dissemination using

bioluminescent imaging (BLI) to monitor viral replication and spread in real time (Figure 4). Dams or pups received CH42 mAb or control IgG either before or after challenge with recombinant HSV-1 that expresses luciferase (36, 37). We performed BLI daily from 2 to 8 days post infection. As expected (12, 29), virus was detected primarily in lungs, trigeminal ganglia, and brain (Figure 4, and Supplemental Figure 2). Among the different treatment and timing modalities tested, offspring of mAb-treated dams cleared the infections fastest compared to control IgG ($p < 0.001$), with nearly undetectable bioluminescence even at the earliest timepoint assessed (Figure 4, A and D). When antibody and virus were administered simultaneously, or when antibody was administered one day following infection, a similar pattern was apparent: bioluminescence diminished more rapidly in CH42- rather than control IgG-treated pups over time and reached background levels by day 6 (Figure 4). While mAb prophylaxis of the pregnant dam resulted in the best viral suppression, co- and post-infection mAb treatment also conferred protection, demonstrating the efficacy of mAb therapy for nHSV.

mAb immunotherapy reduces neurological morbidity in adult mice infected at birth.

Neurological morbidity subsequent to HSV-1 infection of neonates was modeled using the Open Field Test (OFT, Figure 5A), which analyzes the innate exploratory behavior of mice as a measure of anxiety-like behavior (38). Mice are placed in an enclosed arena and the time spent in the periphery relative to the total exploration time (thigmotaxis ratio) is measured. Mice with anxiety-like behavior exhibit higher thigmotaxis ratios (39). Whereas scores of 0.5 are normal in B6 mice, HSV-infected

neonates exhibit elevated thigmotaxis in adulthood (12, 14). We therefore tested whether HSV-specific mAbs could protect mice from exhibiting the anxiety-like behavior that follows neonatal infection. Offspring of control IgG-treated dams spent significantly ($p < 0.05$) more time in the periphery of the arena relative to progeny of CH42-treated dams (Figure 5B). Offspring of CH42-treated dams showed thigmotaxis scores close to 0.5 (Figure 5C), indicating that CH42 was able to protect mice from nHSV-induced behavioral morbidity.

HSV-specific mAbs delivered via vectored immunoprophylaxis (VIP) provide trans-generational protection from nHSV mortality. Having shown that administration of mAbs to dams protects their pups from nHSV mortality, we sought to investigate vectored antibody delivery using AAV. Female mice received a single intramuscular injection of AAV encoding a human mAb (Figure 6A). Serum was obtained over a four-week period to confirm mAb expression (Figure 6B). Transduced dams expressed hulgG in the serum at different levels over a period of approximately 6 months and 3 pregnancies. Progeny of VIP-transduced dams had detectable levels of mAbs in serum (Figure 6C, Supplemental Figure 3A). Furthermore, mAb was effectively transferred throughout visceral organs and the nervous system (Figure 6C). Antibody biodistribution was similar to that observed in neonatal mice that received direct intraperitoneally (IP) injected mAb (Supplemental Figure 3B).

Finally, to assess whether the transferred mAbs were sufficient to protect pups from lethal viral challenge, progeny of VIP-transduced dams were challenged with HSV-1 two days postpartum, and monitored until weaning at three weeks of age. Despite

variation in levels of transferred mAb, progeny of HSV mAb VIP-transduced dams were completely protected from mortality, while progeny of control IgG VIP-transduced dams rapidly succumbed to infection (Figure 6D). These findings demonstrate that antibodies produced *in vivo* in dams via VIP and subsequently transferred to pups were protective ($p < 0.001$). Moreover, although pups from E317 VIP-transduced dams received considerably less mAb, they were equally protected from disease as pups receiving 10-50-fold higher levels of mAbs from their mothers. Together, these findings further underscore the promise of diverse mAb delivery strategies in protection against nHSV-induced morbidity and mortality.

Discussion

A great deal of evidence supports the hypothesis that Abs protect humans and mice against nHSV (9–13, 20, 29, 40–42). Several mAbs, some used in this study, ameliorate acute HSV infection in adult animal models (15–17, 20, 43). Despite this evidence, however, little progress has been made towards Ab-based therapies to treat nHSV in the clinic, and prior trials have relied upon acyclovir and its derivatives. Our experiments demonstrated that diverse mAbs targeting gD protect neonatal mice from lethal viral challenge and neuro-behavioral pathology. Among mAbs tested, HSV8 (35) and UB-621 (22) are currently being evaluated for prevention and/or reduction of adult HSV genital disease (clinical trial identifiers: NCT02579083, NCT04714060, NCT04165122). In light of our results, these mAbs should be considered for the prevention or amelioration of HSV in susceptible neonates.

Clinically, early therapeutic intervention is critical in the setting of nHSV, and delayed acyclovir treatment is associated with increased in-hospital death and morbidity (44). Likewise, our results underscore the importance of early intervention in the setting of mAb-based treatment. Among clinical presentations, disseminated disease has the highest mortality, and CNS disease the highest morbidity (6). Use of the intranasal route of infection, which often results in viral dissemination (12, 29, 40), allowed us to discern if mAbs could reduce viral load in multiple tissues. Maternal mAb administration, either by direct infusion of Ab or through VIP gave near-complete protection to pups from nHSV. These results are consistent with the idea that early prophylactic treatment provides optimum protection. Different mAbs afforded variable protection when directly administered to pups. These differences may be attributed to distinct mechanisms of Ab action (e.g., neutralization, antibody-dependent cellular cytotoxicity, or other effector functions), and/or differences in epitope affinity or specificity. More specifically, consistent with differences in survival between HVEM and Nectin knockout mice challenged with HSV (45–47), the differing receptor binding domains targeted by these mAbs could explain this variation. Overall, we conclude that the mAbs tested in this study are effective, and that the mode and timing of mAb administration are key determinants of protection. These data provide strong support to the idea that pre- and post-exposure mAb administration protects from the acute and long-term sequelae of nHSV infection.

Current clinical strategies to prevent nHSV involve administration of antivirals to mothers with a history of genital herpes or, in cases of primary HSV infection, cesarean section (10, 48). Importantly, our model uses maternal Ab therapy, which has the

potential to protect both mother and neonate. Collectively, we show that mAbs transfer to neonates and distribute to visceral organs and the nervous system. This observation is consistent with the distribution of natural maternally-derived mouse and human Abs (14, 29). In agreement with the hypothesis that Abs protect neural tissues from viral spread (49–51), we see that maternal administration of mAb protected mice from neuro-behavioral pathology. These results represent an exciting opportunity to pursue maternal mAb-based interventions to prevent congenital and perinatal disease in at-risk populations. Adapting the AAV-vectored delivery of Ab, which is safe and durable in humans (52), could provide an avenue for maternal mAb transfer throughout gestation, potentially protecting both mother and baby. Hyperimmune globulin represents an alternative strategy to provide HSV-specific Abs to the maternal-infant dyad, which may also protect from nHSV infection. Recently, this approach was tried to prevent congenital cytomegalovirus (CMV) infection via maternal treatment with CMV hyperimmune globulin. Ultimately, this strategy did not prevent congenital CMV, and treatment with hyperimmune globulin raised concerns over adverse obstetrical outcomes. These adverse outcomes were not statistically significant, but they were consistent with previous studies that also detected slightly higher risk in preterm birth, preeclampsia, and reduced fetal growth (53, 54). In contrast, administration of mAbs during pregnancy has not been associated with these risks (55). Therefore, maternal mAb delivery may prove useful for other congenital and perinatal infections, especially for pathogens for which vaccination has failed or not been attempted.

Infectious disease accounts for approximately one-third of newborn deaths worldwide. Antenatal and perinatal infections of bacterial and viral etiology, including but

not limited to Group B Streptococcus (GBS), CMV, and HSV have devastating consequences. These infections result in significant neonatal death and life-long disability of survivors (6, 7, 56–58). Encouragingly, widespread screening and antenatal antibiotic use have significantly reduced the incidence of neonatal GBS, demonstrating that infection in early life can be circumvented if good therapies exist (59). Viral infections such as CMV and HSV remain a significant danger to neonates. While antiviral treatments have significant benefits in reduction of mortality, they are unable to prevent long term sequelae of nHSV. In the absence of additional interventions such as vaccines or mAbs, consortium and working groups are unlikely to recommend screening, leaving a gap in identifying affected pregnancies/newborns and failing to prevent significant morbidity and mortality even when diagnosed. Therefore, there is a great need to identify effective new therapeutic interventions for antenatal and perinatal infections, as they have tremendous potential to save lives and improve long-term quality of life.

Methods

Mouse procedures. C57BL/6 (B6) and B cell insufficient muMT (B6.129S2-*Ighm*^{tm1Cgn}/J) mice were purchased from The Jackson Laboratory (60). muMT mice were used in a subset of experiments to attribute protection to administered mAb, but results were interchangeable with the B6 mice which were therefore used for follow-up experiments. Blood collection was via cheek bleed from the mandibular vein with a 5mm lancet for weanlings and adults, or a 25 G needle for 1-2 wk old pups. Animals < 1 wk of age were euthanized prior to decapitation for blood collection. Blood samples were allowed to clot

by stasis for ≥ 15 min. and then spun at $2000 \times g$ for 10 min. at 4°C and supernatants collected and stored at -20°C . mAbs were administered IP to pups in $20 \mu\text{L}$ mAb were administered IP. to pregnant dams in volumes between $0.350 - 1 \text{ mL}$. For imaging studies, pups were injected IP with $20 \mu\text{L}$ of 15 mg/mL D-luciferin potassium salt, placed in isoflurane chamber, and moved into the IVIS Xenogen with a warmed stage and continuous isoflurane. Pups were typically imaged 2 days post-infection and serially imaged every other day to monitor bioluminescence. Endpoints for survival studies were defined as excessive morbidity (hunched, spasms, or paralysis) or $>10\%$ weight loss.

Monoclonal antibodies. CH42 and CH43 plasmids were kindly provided by Dr. Tony Moody (Duke University). When expressed *in vitro*, CH42 contained the Fc mutation known as AAA (S298A/E333A/K334A), which enhances antibody dependent cellular cytotoxicity (61). E317 is the original clone of the clinical drug product UB-621; its heavy and light chain variable sequences were derived from published amino acid sequences (18) and synthesized in-house. The heavy and light chain variable sequences were ordered as “gBlocks” (Integrated DNA technologies) and cloned to an IgG1 heavy chain backbone, and a kappa light chain backbone. In-house expressed antibodies were made through co-transfection of heavy and light chain plasmids in Expi293 HEK cells (Thermo Fisher) according to the manufacturer’s instructions. Seven days after transfection, cultures were spun at $3000 \times g$ for 30 minutes to pellet the cells, and supernatants were filtered ($0.22 \mu\text{m}$). IgG was affinity purified using a custom packed 5 mL protein A column with a retention time of 1 minute (ie. 5 mL/min) and eluted with 100

mM glycine pH 3, which was immediately neutralized with 1 M Tris buffer pH 8. Eluate was then concentrated to 2.5 mL for size exclusion chromatography on a HiPrep Sephacryl S-200 HR column using an AktaPure FPLC at a flow rate of 1 mL/min of sterile PBS. Fractions containing monomeric IgG were pooled and concentrated using spin columns (Amicon UFC903024) to approximately 2 mg/mL of protein and either used within a week or aliquoted and frozen at -80°C for later use. HSV8 mAb was kindly provided by ZabBio, and UB-621, a clinical grade antibody preparation with the E317 gene sequence expressed in hamster ovary cells, was kindly provided by United Biopharma.

Viral challenge. The wild-type viral strains used in this study were HSV-1 17syn+(62), HSV-2 G (kindly provided by Dr. David Knipe) (63). The bioluminescent luciferase-expressing recombinant virus HSV-1 17syn+/Dlux was constructed as previously described (37). Viral stocks were prepared using Vero cells as previously described (64, 65). Newborn pups were infected intranasally on day 1 or 2 postpartum with indicated amounts of HSV in a volume of 5 µl under isoflurane anesthesia. Pups were then monitored for survival, imaging, or behavior studies once adulthood was reached as appropriate. For survival studies, pups were challenged with 1×10^3 or 1×10^4 plaque forming units (pfu) of HSV-1 (Strain 17), and 3×10^2 pfu of HSV-2 (Strain G) as indicated. For imaging studies, pups were challenged with 1×10^5 pfu of HSV-1 17syn+/Dlux.

Whole body cryo-macrotome imaging procedures. Conjugation of mAb UB-621 was as previously described (66). Briefly, 5 mg of mAb in 100 µL of PBS was incubated with 10

346 μ L of filter-sterilized 1M sodium bicarbonate and 1 μ L of 10 mg/mL AF488 NHS-ester
 347 (Lumiprobe) for 1 hr. at room temperature and protected from light. Buffer exchange
 348 was carried out with Zeba spin columns (Thermo). Conjugation was confirmed through
 349 flow cytometry and spectrophotometer readings before animal experiments were
 350 performed. B6 dams were bred for timed pregnancies, and on day 11 of gestation
 351 chlorophyll-free diet (MP Biomedical) was initiated to reduce autofluorescence. On day
 352 16 of gestation 5 mg AF488 labeled UB-621 was administered via tail-vein, and 2 days
 353 later animals were sacrificed and prepared for cryo-imaging by OCT (Tissue-Tek)
 354 flooding and subsequent freezing at -20 °C. The hyperspectral imaging whole body
 355 cryo-macrotome instrument has been described previously (67). Briefly, the system
 356 operates by automatically sectioning frozen specimens in a slice-and-image sequence,
 357 acquiring images of the specimen block after each section is removed. For this study,
 358 we acquired brightfield and AF488 fluorescence volumes of each animal at a resolution
 359 of 150 μ m in the sectioning direction and ~100 μ m in the imaging plane. Hyperspectral
 360 fluorescence images were spectrally unmixed using known fluorophore and tissue
 361 spectral bases to isolate the AF488 signal in animal tissue. The acquired image stacks
 362 were then combined in an open-source software platform (Slicer 4.11) to generate high-
 363 resolution three-dimensional volumes of the brightfield and fluorophore distribution
 364 throughout whole-body animal models.

365
 366 *Adeno-associated virus (AAV) production and procedure.* AAVs encoding the heavy and
 367 light chain sequences of CH42, CH43, and E317, and control IgG mAbs with the same
 368 human IgG1 backbone were produced as previously described (24). A single 40 μ l

injection of 1×10^{11} genome copies of AAV was administered into the gastrocnemius muscle of B6 mice as previously described (24). Blood samples were obtained by cheek bleed to verify antibody expression.

Assessment of mAb expression and biodistribution. A magnetic bead-based assay (68) was used to measure antibody expression and biodistribution. Beads were conjugated to anti-human antigen-binding fragment (Fab) to capture mAbs of interest. Briefly, anti-human IgG F(ab')₂ fragment (Jackson Immune Research) was conjugated to fluorescent microspheres (MagPlex-C Microspheres, Luminex Corp.) at a ratio of 6.5 µg protein/100 µL microspheres. Samples were incubated with microspheres (500 -750 beads/well) overnight at 4°C and washed in PBS with 1% BSA, 0.05% Tween-20, and 0.1% sodium azide. Anti-human IgG PE (Southern Biotech) was incubated at 0.65 µg/mL for 45 min in PBS-TBN. The microspheres were washed and resuspended in 90 µl of sheath fluid (Luminex) and read using a Bio-plex array reader (FlexMap 3D, OR MAGPIX). The median fluorescence intensity (MFI) of the PE signal was determined for each sample at indicated dilutions. For biodistribution assessment signal is reported as the fold increase in PE signal in treated pups relative to untreated controls.

Behavioral tests and analysis. Animals were transferred to a dedicated behavior testing room at least one week before tests began. Environmental conditions, such as lighting, temperature, and noise levels were kept consistent. Behavioral tests and analysis were performed by independent, masked operators. The Open Field Test was performed as previously described (12). Briefly, 5- to 7-week-old B6 mice were placed in the open

field arena (30 cm x 30 cm) and allowed to habituate for 10 mins before data collection took place for an additional 10 mins. The movement of animals was recorded (Canon Vixia HFM52) and videos were analyzed using open-source software (69).

Statistical Analysis. Prism 8 GraphPad software was used for statistical tests unless otherwise described. For survival studies, HSV-specific mAbs were compared to isotype controls using the Log-rank Mantel-Cox test to determine *p* values. For imaging studies, groups and time points were compared to each other via two-way ANOVA, with Sidak's test for multiple comparisons to determine *p* values.

Study Approval

Procedures were performed in accordance with Dartmouth's Center for Comparative Medicine and Research policies, and following approval by the institutional animal care and use committee.

Acknowledgements

We gratefully appreciate Audra J. Charron for editing of the manuscript and thoughtful discussion. We acknowledge Alexey Khalenkov for construction of HSV-1 17syn+/Dlux, and appreciate Jennifer Fields for aid in animal studies. We also thank members of the Leib and Ackerman labs for materials and/or helpful discussion.

These studies were supported by NIH grants to DAL (R21 AI147714-01 to DAL and MEA, PO1 AI098681, and RO1 09083). A.B.B. is supported by the National Institutes for Drug

Abuse (NIDA) Avenir New Innovator Award DP2DA040254, the MGH Transformative Scholars Program as well as funding from the Charles H. Hood Foundation. This independent research was supported by the Gilead Sciences Research Scholars Program in HIV.

Authorship Contributions

I.M.B., S.C.D., A.B.B., M.E.A., D.A.L. designed and analyzed the research. I.M.B., B.K.B., C.D.P., S.A.T., C.R.G., S.W.M. performed experiments, and/or made materials, engaged in discussion, assisted with animal care and data analysis. I.M.B. drafted the manuscript and prepared figures, M.E.A., and D.A.L. edited the manuscript and figure legends, other authors contributed comments and edits.

References

1. Williams EJ et al. Viral Infections: Contributions to Late Fetal Death, Stillbirth, and Infant Death. *J. Pediatr.* 2013;163(2):424–428.
2. Slutsker JS, Schillinger JA. Assessing the Burden of Infant Deaths Due to Herpes Simplex Virus, Human Immunodeficiency Virus, and Congenital Syphilis: United States, 1995 to 2017. *Sex. Transm. Dis.* 2021;48(8S):S4–S10.
3. Brown ZA et al. The Acquisition of Herpes Simplex Virus during Pregnancy. *N. Engl. J. Med.* 1997;337(8):509–516.
4. Looker KJ et al. First estimates of the global and regional incidence of neonatal herpes infection. *Lancet Glob. Health* 2017;5(3):e300–e309.
5. Mahant S et al. Neonatal Herpes Simplex Virus Infection Among Medicaid-Enrolled Children: 2009–2015. *Pediatrics* 2019;143(4):e20183233.
6. Whitley R et al. Predictors of morbidity and mortality in neonates with herpes simplex virus infections. The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. *N. Engl. J. Med.* 1991;324(7):450–454.
7. Corey L, Wald A. Maternal and Neonatal Herpes Simplex Virus Infections. *N. Engl. J. Med.* 2009;361(14):1376–1385.
8. Whitley RJ et al. The Natural History of Herpes Simplex Virus Infection of Mother and Newborn. *Pediatrics* 1980;66(4):489–494.
9. Brown ZA et al. Neonatal Herpes Simplex Virus Infection in Relation to Asymptomatic Maternal Infection at the Time of Labor. *N. Engl. J. Med.* 1991;324(18):1247–1252.

10. Brown ZA et al. Effect of Serologic Status and Cesarean Delivery on Transmission Rates of Herpes Simplex Virus From Mother to Infant. *JAMA* 2003;289(2):203–209.
11. Kohl S. Role of Antibody-Dependent Cellular Cytotoxicity in Neonatal Infection with Herpes Simplex Virus. *Clin. Infect. Dis.* 1991;13(Supplement_11):S950–S952.
12. Patel CD et al. Maternal immunization confers protection against neonatal herpes simplex mortality and behavioral morbidity. *Sci. Transl. Med.* 2019;11(487):eaau6039.
13. Patel CD et al. Trivalent Glycoprotein Subunit Vaccine Prevents Neonatal Herpes Simplex Virus Mortality and Morbidity. *J. Virol.* 2020;94(11):e02163-19.
14. Patel CD. Harnessing Maternal Humoral Immunity to Prevent Neonatal Herpes Neurological Sequela. [PhD thesis]. Hanover, NH, USA: Dartmouth College; 2020.
15. Wang K et al. Monoclonal Antibodies, Derived from Humans Vaccinated with the RV144 HIV Vaccine Containing the HVEM Binding Domain of Herpes Simplex Virus (HSV) Glycoprotein D, Neutralize HSV Infection, Mediate Antibody-Dependent Cellular Cytotoxicity, and Protect Mice from Ocular Challenge with HSV-1. *J. Virol.* 2017;91(19):e00411-17, /jvi/91/19/e00411-17.atom.
16. Krawczyk A et al. Overcoming drug-resistant herpes simplex virus (HSV) infection by a humanized antibody. *Proc. Natl. Acad. Sci.* 2013;110(17):6760–6765.
17. Sanna PP et al. Protection of Nude Mice by Passive Immunization with a Type-Common Human Recombinant Monoclonal Antibody against HSV. *Virology* 1996;215(1):101–106.
18. Lai J-S, Lin Y-S, Chan W-E. Anti-herpes simplex virus antibodies 2010; <https://patents.google.com/patent/WO2010087813A1/en>. cited May 10, 2021

478 19. Lai J-S, Chan W-E. Anti-herpes simplex virus antibodies and methods of use thereof 2013;
479 <https://patents.google.com/patent/US8431118/en>. cited May 1, 2020

480 20. Kohl S, Strynadka NC, Hodges RS, Pereira L. Analysis of the role of antibody-dependent
481 cellular cytotoxic antibody activity in murine neonatal herpes simplex virus infection with
482 antibodies to synthetic peptides of glycoprotein D and monoclonal antibodies to glycoprotein B..
483 *J. Clin. Invest.* 1990;86(1):273–278.

484 21. Lee C-C et al. Structural basis for the antibody neutralization of *Herpes simplex virus*. *Acta*
485 *Crystallogr. D Biol. Crystallogr.* 2013;69(10):1935–1945.

486 22. Clementi N et al. Novel therapeutic investigational strategies to treat severe and
487 disseminated HSV infections suggested by a deeper understanding of in vitro virus entry
488 processes. *Drug Discov. Today* 2016;21(4):682–691.

489 23. Burioni R, Williamson RA, Sanna PP, Bloom FE, Burton DR. Recombinant human Fab to
490 glycoprotein D neutralizes infectivity and prevents cell-to-cell transmission of herpes simplex
491 viruses 1 and 2 in vitro.. *Proc. Natl. Acad. Sci.* 1994;91(1):355–359.

492 24. Balazs AB et al. Antibody-based protection against HIV infection by vectored
493 immunoprophylaxis. *Nature* 2012;481(7379):81–84.

494 25. Balazs AB, Bloom JD, Hong CM, Rao DS, Baltimore D. Broad protection against influenza
495 infection by vectored immunoprophylaxis in mice. *Nat. Biotechnol.* 2013;31(7):647–652.

496 26. Balazs AB et al. Vectored immunoprophylaxis protects humanized mice from mucosal HIV
497 transmission. *Nat. Med.* 2014;20(3):296–300.

498 27. Jong YP et al. Broadly neutralizing antibodies abrogate established hepatitis C virus
499 infection. *Sci. Transl. Med.* 2014;6(254):254ra129.

500 28. Deal C et al. Vectored antibody gene delivery protects against *Plasmodium falciparum*
501 sporozoite challenge in mice. *Proc. Natl. Acad. Sci. U. S. A.* 2014;111(34):12528–12532.

502 29. Jiang Y et al. Maternal Antiviral Immunoglobulin Accumulates in Neural Tissue of Neonates
503 To Prevent HSV Neurological Disease. *mBio* 2017;8(4):e00678-17, /mbio/8/4/e00678-17.atom.

504 30. Soter JA et al. Tracking tumor radiotherapy response in vivo with Cherenkov-excited
505 luminescence ink imaging. *Phys. Med. Biol.* 2020;65(9):095004.

506 31. Kim J et al. FcRn in the yolk sac endoderm of mouse is required for IgG transport to fetus. *J.*
507 *Immunol. Baltim. Md* 1950 2009;182(5):2583–2589.

508 32. De Logu A et al. Characterization of a Type-Common Human Recombinant Monoclonal
509 Antibody to Herpes Simplex Virus with High Therapeutic Potential. *J. Clin. Microbiol.*
510 1998;36(11):3198–3204.

511 33. Zawatzky R, Engler H, Kirchner HY 1982. Experimental Infection of Inbred Mice with Herpes
512 Simplex Virus. III. Comparison between Newborn and Adult C57BL/6 Mice. *J. Gen. Virol.*
513 1982;60(1):25–29.

514 34. Kohl S, Loo LS. Ontogeny of murine cellular cytotoxicity to herpes simplex virus-infected
515 cells.. *Infect. Immun.* 1980;30(3):847–850.

516 35. Politch JA et al. Safety, acceptability, and pharmacokinetics of a monoclonal antibody-based
517 vaginal multipurpose prevention film (MB66): A Phase I randomized trial. *PLoS Med.*
518 2021;18(2):e1003495.

519 36. Summers BC, Margolis TP, Leib DA. Herpes Simplex Virus Type 1 Corneal Infection
520 Results in Periocular Disease by Zosteriform Spread. *J. Virol.* 2001;75(11):5069–5075.

521 37. Luker GD et al. Noninvasive Bioluminescence Imaging of Herpes Simplex Virus Type 1
522 Infection and Therapy in Living Mice. *J. Virol.* 2002;76(23):12149–12161.

523 38. Seibenhener ML, Wooten MC. Use of the Open Field Maze to Measure Locomotor and
524 Anxiety-like Behavior in Mice. *J. Vis. Exp.* 2015;(96):52434.

525 39. Simon P, Dupuis R, Costentin J. Thigmotaxis as an index of anxiety in mice. Influence of
526 dopaminergic transmissions. *Behav. Brain Res.* 1994;61(1):59–64.

527 40. Kao CM et al. Murine Model of Maternal Immunization Demonstrates Protective Role for
528 Antibodies That Mediate Antibody-Dependent Cellular Cytotoxicity in Protecting Neonates From
529 Herpes Simplex Virus Type 1 and Type 2. *J. Infect. Dis.* 2019;jiz521.

530 41. Evans IAC, Jones CA. Maternal Immunization with a Herpes Simplex Virus Type 2
531 Replication-Defective Virus Reduces Visceral Dissemination but Not Lethal Encephalitis in
532 Newborn Mice after Oral Challenge. *J. Infect. Dis.* 2002;185(11):1550–1560.

533 42. Yeager AS, Arvin AM, Urbani LJ, Kemp JA. Relationship of Antibody to Outcome in
534 Neonatal Herpes Simplex Virus Infections:. *Obstet. Gynecol. Surv.* 1981;36(4):191–192.

535 43. Kimberlin DM. Immunotherapy of HSV infections – antibody delivery. In: Arvin A et al eds.
536 *Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis*. Cambridge: Cambridge
537 University Press; 2007:

538 44. Shah SS, Aronson PL, Mohamad Z, Lorch SA. Delayed Acyclovir Therapy and Death
539 Among Neonates With Herpes Simplex Virus Infection. *PEDIATRICS* 2011;128(6):1153–1160.

540 45. Kopp SJ et al. Herpes simplex virus serotype and entry receptor availability alter CNS
541 disease in a mouse model of neonatal HSV. *Pediatr. Res.* 2014;76(6):528–534.

542 46. Kopp SJ et al. Pathogenesis of neonatal herpes simplex 2 disease in a mouse model is
543 dependent on entry receptor expression and route of inoculation. *J. Virol.* 2013;87(1):474–481.

544 47. Kopp SJ et al. Infection of neurons and encephalitis after intracranial inoculation of herpes
545 simplex virus requires the entry receptor nectin-1. *Proc. Natl. Acad. Sci. U. S. A.*
546 2009;106(42):17916–17920.

547 48. Sheffield JS et al. Valacyclovir Prophylaxis to Prevent Recurrent Herpes at Delivery: A
548 Randomized Clinical Trial. *Obstet. Gynecol.* 2006;108(1):141–147.

549 49. McKendall RR, Klassen T, Baringer JR. Host defenses in herpes simplex infections of the
550 nervous system: effect of antibody on disease and viral spread. *Infect. Immun.* [published online
551 ahead of print: February 1979]; doi:10.1128/iai.23.2.305-311.1979

552 50. Oakes JE. Invasion of the Central Nervous System by Herpes Simplex Virus Type 1 after
553 Subcutaneous Inoculation of Immunosuppressed Mice. *J. Infect. Dis.* 1975;131(1):51–57.

554 51. Dix RD, Pereira L, Baringer JR. Use of monoclonal antibody directed against herpes simplex
555 virus glycoproteins to protect mice against acute virus-induced neurological disease. *Infect.*
556 *Immun.* 1981;34(1):192–199.

557 52. Drug-delivery technology leads to sustained HIV antibody production in NIH study. *Natl. Inst.*
558 *Health NIH* 2020; [https://www.nih.gov/news-events/news-releases/drug-delivery-technology-](https://www.nih.gov/news-events/news-releases/drug-delivery-technology-leads-sustained-hiv-antibody-production-nih-study)
559 [leads-sustained-hiv-antibody-production-nih-study](https://www.nih.gov/news-events/news-releases/drug-delivery-technology-leads-sustained-hiv-antibody-production-nih-study). cited September 22, 2021

560 53. Revello MG et al. A Randomized Trial of Hyperimmune Globulin to Prevent Congenital
561 Cytomegalovirus. *N. Engl. J. Med.* 2014;370(14):1316–1326.

562 54. Hughes BL et al. A Trial of Hyperimmune Globulin to Prevent Congenital Cytomegalovirus
563 Infection. *N. Engl. J. Med.* 2021;385(5):436–444.

564 55. Pham-Huy A, Top KA, Constantinescu C, Seow CH, El-Chaâr D. The use and impact of
565 monoclonal antibody biologics during pregnancy. *CMAJ* 2021;193(29):E1129–E1136.

566 56. Franciosi RA, Knostman JD, Zimmerman RA. Group B streptococcal neonatal and infant
567 infections. *J. Pediatr.* 1973;82(4):707–718.

568 57. Stagno S, Pass RF, Dworsky ME, Alford CA. Maternal cytomegalovirus infection and
569 perinatal transmission. *Clin. Obstet. Gynecol.* 1982;25(3):563–576.

570 58. Stagno S et al. Primary cytomegalovirus infection in pregnancy. Incidence, transmission to
571 fetus, and clinical outcome. *JAMA* 1986;256(14):1904–1908.

572 59. Committee on Obstetrics Practice. Prevention of Group B Streptococcal Early-Onset
573 Disease in Newborns: ACOG Committee Opinion, Number 797. *Obstet. Gynecol.*
574 2020;135(2):e51–e72.

575 60. Kitamura D, Roes J, Kühn R, Rajewsky K. A B cell-deficient mouse by targeted disruption of
576 the membrane exon of the immunoglobulin mu chain gene. *Nature* 1991;350(6317):423–426.

577 61. Shields RL et al. High Resolution Mapping of the Binding Site on Human IgG1 for FcγRI,
578 FcγRII, FcγRIII, and FcRn and Design of IgG1 Variants with Improved Binding to the FcγR*. *J.*
579 *Biol. Chem.* 2001;276(9):6591–6604.

580 62. Brown SM, Ritchie DA, Subak-Sharpe JH. Genetic Studies with Herpes Simplex Virus Type
581 1. The Isolation of Temperature-sensitive Mutants, their Arrangement into Complementation
582 Groups and Recombination Analysis Leading to a Linkage Map. *J. Gen. Virol.* 1973;18(3):329–
583 346.

584 63. Ejercito PM, Kieff ED, Roizman B. Characterization of Herpes Simplex Virus Strains
585 Differing in their Effects on Social Behaviour of Infected Cells. *J. Gen. Virol.* 1968;2(3):357–364.

64. Manivanh R, Mehrbach J, Knipe DM, Leib DA. Role of Herpes Simplex Virus 1 γ 34.5 in the Regulation of IRF3 Signaling. *J. Virol.* 91(23):e01156-17.
65. Rader KA, Ackland-Berglund CE, Miller JK, Pepose JS, Leib DA. In vivo characterization of site-directed mutations in the promoter of the herpes simplex virus type 1 latency-associated transcripts. *J. Gen. Virol.* 1993;74 (Pt 9):1859–1869.
66. Schneider JR et al. Long-term direct visualization of passively transferred fluorophore-conjugated antibodies. *J. Immunol. Methods* 2017;450:66–72.
67. Fitzgerald JE et al. Heterogeneity of circulating tumor cell dissemination and lung metastases in a subcutaneous Lewis lung carcinoma model. *Biomed. Opt. Express* 2020;11(7):3633–3647.
68. Brown EP et al. High-throughput, multiplexed IgG subclassing of antigen-specific antibodies from clinical samples. *J. Immunol. Methods* 2012;386(1–2):117–123.
69. Patel TP et al. An open-source toolbox for automated phenotyping of mice in behavioral tasks. *Front. Behav. Neurosci.* 2014;8:349.

Figures and Legends

Graphical Abstract. Different antibody sources were used to maternally-transfer or directly administer HSV-specific mAbs to mouse pups. Neonatal mice were challenged with wild type or bioluminescent virus before or after mAb acquisition. Following infection, pups were assessed for survival, virus-induced bioluminescence and anxiety-like behavior as a measure of neurological morbidity. Efficacy was time and mAb dependent. Notably, all HSV-specific mAbs prevented nHSV-associated mortality.

637

638

639

640

641

642

643

644

645

646

647

648

649

650

651

652

653

Figure 1. Fluorescently labeled mAb accumulates at the placental-fetal interface. To assess maternally administered Ab biodistribution, conjugated Ab was administered intravenously (IV) on day 15 or 16 of gestation, then 2-3 days later tissues were prepared for whole body imaging using the cryo-macrotome. **(A)** Background fluorescence levels in a pregnant dam not injected with conjugated Ab. **(B)** Accumulation of fluorescently labeled UB-621 Ab in a pregnant dam two days following IV administration. **(C)** Accumulation of fluorescently labeled Ab in conceptuses that were harvested from the murine uterus, with maternal and fetal layers removed as indicated.

Figure 2. Epitope map of HSV-specific mAbs that target the viral entry mediator gD. (A) Linear representation of the gD extracellular domain with the HVEM binding domain (yellow) and Nectin-1 domain (black). UB-621 is derived from the original clone of E317. The exact contact residues of HSV8 are not known, but shown is an approximation based on reactivity against gD residues 235 -275. **(B)** The gD ectodomain space filling structure (PDB: JMA1) with cell receptor binding domains and mAb epitopes denoted by specific colors shown in panel A, as follows: Red = CH42, pink = CH43, blue = E317, purple = HSV8.

Figure 3. Prophylactic and therapeutic HSV-specific mAbs prevent nHSV-associated mortality. Abs were delivered intraperitoneally to pregnant dams, or pups. Pups were challenged intranasally two days post-partum with indicated viral dose, then observed to DPI 21. (A) Survival of pups following CH42 (red) or IgG control (ctrl, black) administration to pregnant dams five days before infection. (B) Survival of pups following administration of E317 (blue) or IgG control (black) one day before infection in solid lines, or CH42 (red) or IgG control (black) one day post infection in dashed lines. (C) Survival of pups following HSV8 (purple), UB-621 (teal), CH42 (red), or IgG control (black) administration immediately before infection with HSV-1 or HSV-2. Statistical significance was determined by the Log-rank (Mantel-Cox) test; HSV-specific mAbs are compared to IgG control (ctrl). (* p < 0.05, ** p < 0.01, *** p < 0.001). DPI, day post infection, PFU, plaque forming unit.

Figure 4. Administration of CH42 reduces viral dissemination. Pregnant dams or pups received injections of CH42 or IgG control (ctrl) antibody before or after viral challenge with a luciferase-expressing reporter HSV-1. Pups were imaged on DPI 2, then imaged until DPI 8. Representative images follow the same two pups sequentially. (A) Bioluminescence imaging of pups following CH42 or IgG control administration to pregnant dams five days before infection. (B) Bioluminescence imaging of pups following IP mAb administration and immediate subsequent viral challenge. (C) Bioluminescence imaging of pups following IP mAb administration one day after infection. (D) Quantification of the virally-derived bioluminescence shown in panels A, B & C. Statistical significance was determined by two-way ANOVA, and Šídák's method for multiple comparisons (** p < 0.01, *** p < 0.001, **** p < 0.0001).

Figure 5. Offspring of HSV-specific mAb treated dams are protected from behavioral morbidity. Pregnant B6 mice were administered CH42 or IgG control (ctrl) mAbs, then progeny were challenged with luciferase expressing HSV-1, after 5 weeks mice were behaviorally assessed at 5 weeks. **(A)** Anxiety-like behavior analysis via the open field test (OFT) of adult mice infected on day two post-partum. Representative traces and heatmaps illustrate the pattern of movement, as well as the time spent in specific areas. **(B)** Thigmotaxis ratio of adult mice assessed for anxiety-like behavior via the OFT. Thigmotaxis is a measure of anxiety, a normal score = 0.5, higher scores indicate increased anxiety. Statistical significance was determined by unpaired t test (* $p < 0.05$).

Figure 6. VIP-derived HSV-specific transferred mAbs protect pups from nHSV mortality. VIPs encoding 4 different mAb sequences were administered to female mice. Progeny were assessed for Ab transfer and protection from viral challenge. **(A)** Schematic of AAV human IgG expression vector structure and experimental approach. **(B)** Detection of *in vivo* expressed hulgG in the serum of VIP-administered female mice from week 0 through 4. **(C)** Biodistribution of human IgG in the viscera, brain, trigeminal ganglia and serum of offspring of VIP-treated dams. Signal is reported as the fold increase in human IgG in treated pups relative to untreated controls. **(D)** Survival of progeny of VIP-administered dams challenged with 1×10^4 PFU of HSV-1 two days post-partum. Statistical significance was determined by the Log-rank (Mantel-Cox) test; HSV-specific mAbs are compared to IgG control (ctrl). (***) $p < 0.001$.